Trial Profile

A Pilot Study of Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2: A Decentralized Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enasidenib (Primary)
Indications Acute myeloid leukaemia; Cytopenia; Myelodysplastic syndromes
Focus Therapeutic Use

Most Recent Events

11 Feb 2026 Planned End Date changed from 30 Jun 2027 to 28 Feb 2029.
11 Feb 2026 Planned primary completion date changed from 31 May 2027 to 31 Jan 2028.
31 Jul 2025 Planned End Date changed from 31 Oct 2026 to 30 Jun 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com